IL6 and pancreatic adenocarcinoma: found that in pancreatic adenocarcinomas (PDACs) patients, cDC2s were systematically suppressed by significantly increased IL-6, as IL-6 disrupted the polarization of cDC1s and cDC2s, impaired antigen processing and presentation functions, resulting in anti-tumor immunity being affected (44).